Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

epcoritamab-bysp

- PMLiVE

AbbVie announces CHMP recommendation for Tepkinly in follicular lymphoma

The blood cancer accounts for up to 30% of all non-Hodgkin lymphoma cases

- PMLiVE

AbbVie expands inflammatory disease pipeline with $250m Celsius acquisition

The deal includes an anti-TREM1 antibody that has completed a phase 1 study in inflammatory bowel disease

- PMLiVE

FDA publishes guidance on diversity action plans to improve enrolment in clinical trials

The guidance will help to enhance the understanding of a disease or medical product being studied

- PMLiVE

AbbVie/Genmab’s Epkinly granted FDA accelerated approval to treat follicular lymphoma

Approximately 15,000 people develop the form of non-Hodgkin lymphoma every year in the US

- PMLiVE

FDA approves Verona’s Ohtuvayre as COPD maintenance treatment in adults

More than 390 million people worldwide are living with COPD and about half of patients experience almost daily symptoms

- PMLiVE

FDA approves argenx’s Vyvgart Hytrulo for rare neuromuscular disorder CIDP

Approximately 24,000 US patients are currently being treated for chronic inflammatory demyelinating polyneuropathy

- PMLiVE

Bristol Myers Squibb’s Krazati granted FDA accelerated approval in colorectal cancer

More than 106,000 new cases of the disease are expected to be diagnosed in the US this year

- PMLiVE

FDA expands indication for Sarepta’s Duchenne muscular dystrophy gene therapy Elevidys

The neuromuscular condition is estimated to affect one in every 3,500 male births worldwide

- PMLiVE

Merck’s adult-specific pneumococcal vaccine Capvaxive granted FDA approval

The vaccine is designed to protect against the strains responsible for the majority of adult invasive pneumococcal disease

- PMLiVE

AbbVie’s IL-23 inhibitor Skyrizi approved by FDA to treat ulcerative colitis in adults

The inflammatory bowel disease affects more than one million people in the US

- PMLiVE

Merck’s Keytruda regimen granted FDA approval to treat endometrial cancer

Approximately 67,880 new cases of uterine cancer will be diagnosed in the US this year

- PMLiVE

Amgen’s Blincyto approved by FDA for new acute lymphoblastic leukaemia indication

More than 6,500 new cases of the blood cancer were diagnosed in the US last year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links